Research Topics
Species | Simon J DraperSummaryAffiliation: University of Oxford Country: UK Publications
| Collaborators
|
Detail Information
Publications
The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19)Jianguo Shi
Institute of Genetics, Queen s Medical Centre, University of Nottingham, NG7 2UH, UK
BMC Biotechnol 11:77. 2011..Although human serum immunoglobulin A (IgA) is the second most abundant class of antibody in the circulation, its contribution, if any, to protective responses against malaria is not clear...
Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccinesSimon J Draper
Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
J Immunol 185:7583-95. 2010..These data encourage the further clinical development and coadministration of protein and viral vector vaccine platforms in an attempt to induce broad cellular and humoral immune responses against blood-stage malaria Ags in humans...- Effective induction of high-titer antibodies by viral vector vaccinesSimon J Draper
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
Nat Med 14:819-21. 2008..Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro... - Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malariaSimon J Draper
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
Cell Host Microbe 5:95-105. 2009..Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1... - Viruses as vaccine vectors for infectious diseases and cancerSimon J Draper
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK
Nat Rev Microbiol 8:62-73. 2010.... - Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectorsSusanne H Sheehy
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
Mol Ther 19:2269-76. 2011..Further studies are required to assess whether this strategy can achieve protective efficacy against blood-stage malaria infection... - Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protectionSumi Biswas
Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
J Immunol 188:5041-53. 2012.... - Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsSusanne H Sheehy
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
PLoS ONE 7:e31208. 2012..falciparum. The development of a vaccine that could induce both cell-mediated and humoral immune responses would enable important proof-of-concept efficacy studies to be undertaken to address this question... 
Prime-boost vectored malaria vaccines: progress and prospectsAdrian V S Hill
The Jenner Institute, University of Oxford, Oxford, UK
Hum Vaccin 6:78-83. 2010..These viral vectors now provide a major option for inclusion in a high efficacy multi-stage malaria vaccine that should achieve deployable levels of efficacy in endemic settings...- Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interferenceEmily K Forbes
The Jenner Institute, University of Oxford, Oxford, United Kingdom
J Immunol 187:3738-50. 2011..These data have important implications for the development of a multistage or multicomponent viral vectored malaria vaccine for use in humans... - Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1Sumi Biswas
The Jenner Institute, University of Oxford, Oxford, Oxfordshire, United Kingdom
PLoS ONE 6:e20977. 2011..Here we describe the pre-clinical development and optimization of recombinant human and simian adenoviral (AdHu5 and ChAd63) and orthopoxviral (MVA) vectors encoding transgene inserts for Plasmodium falciparum AMA1 (PfAMA1)... - Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primatesAlexandra J Spencer
The Jenner Institute, University of Oxford, Oxford, United Kingdom
PLoS ONE 7:e33555. 2012..This report demonstrates that antigen multimerization using IMX313 is a simple and effective cross-species method to improve vaccine immunogenicity with potentially broad applicability... - The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibodyAlexander D Douglas
Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
Nat Commun 2:601. 2011..falciparum is a degenerate process involving a series of parallel redundant pathways... - Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1Alexander D Douglas
Jenner Institute, Oxford University, Oxford, UK
Vaccine 28:7167-78. 2010.... - The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirusSimone C de Cassan
The Jenner Institute, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom
J Immunol 187:2602-16. 2011.... - Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptorsMatthew N Davies
The Jenner Institute, University of Oxford, Newbury, Berkshire, United Kingdom
PLoS ONE 4:e8084. 2009..An antagonist of the chemokine CCR4 receptor can display adjuvant-like properties by diminishing the ability of CD4+CD25+ regulatory T cells (Tregs) to down-regulate immune responses... - Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infectionSean C Elias
The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
J Immunol 190:1135-47. 2013..We also show that controlled infection with 3D7 strain P. falciparum parasites neither boosts existing 3D7-specific T cell responses nor appears to "immune divert" cellular responses toward the Wellcome allele... - ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humansSusanne H Sheehy
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
Mol Ther 20:2355-68. 2012..These data call into question the utility of T cell-inducing blood-stage malaria vaccines and suggest that the focus should remain on high-titer antibody induction against susceptible antigen targets... - T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding proteinEmily K Forbes
The Jenner Institute, University of Oxford, Oxford, United Kingdom
PLoS ONE 7:e44943. 2012..The oligomerization domain of C4 bp can thus adjuvant T cell responses induced by AdHu5 vectors against selected antigens and its clinical utility as well as mechanism of action warrant further investigation... - Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
PLoS ONE 6:e22271. 2011..Here we report the first study to examine the relationship between in vivo Plasmodium falciparum growth rates and in vitro GIA in humans experimentally infected with blood-stage malaria... - A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activityAnna L Goodman
The Jenner Institute, University of Oxford, Oxford, United Kingdom
PLoS ONE 6:e29428. 2011.... - Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominanceAnne C Moore
Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, United Kingdom
J Immunol 175:7264-73. 2005..Vaccine strategies incorporating anti-CD25 lead to improved protection against pre-erythrocytic malaria challenge. These data underpin new strategies for the design and development of more efficacious vaccines in clinical settings... - Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigensAndrew R Williams
The Jenner Institute, University of Oxford, Oxford, United Kingdom
PLoS Pathog 8:e1002991. 2012..falciparum antigens and should help to guide the rational development of future multi-antigen vaccines... - Controlled human blood stage malaria infection: current status and potential applicationsChristopher J A Duncan
Sir William Dunn School of Pathology, University of Oxford, United Kingdom
Am J Trop Med Hyg 86:561-5. 2012..We summarize clinical, parasitologic, and immunologic data from all BSP challenges to date, explore differences between the BSP and sporozoite models, and propose future applications for BSP challenge... - In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccinationJagadeesh Bayry
The Edward Jenner Institute for Vaccine Research, University of Oxford, Compton, United Kingdom
Proc Natl Acad Sci U S A 105:10221-6. 2008..The significant adjuvant activity observed provides good evidence supporting our hypothesis that CCR4 is a viable target for rational adjuvant design... - Accelerating vaccine development and deployment: report of a Royal Society satellite meetingMigena Bregu
Jenner Institute, University of Oxford, Oxford, UK
Philos Trans R Soc Lond B Biol Sci 366:2841-9. 2011....